EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group

L. Y. Dirix; F. Tonnesen; J. Cassidy; R. Epelbaum; W. W. Ten Bokkel Huinink; N. Pavlidis; R. Sorio; T. Gamucci; I. Wolff; A. Te Velde; J. Lan; J. Verweij

doi:10.1016/0959-8049(96)00226-2

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group

L. Y. Dirix, F. Tonnesen, J. Cassidy, R. Epelbaum, W. W. Ten Bokkel Huinink, N. Pavlidis, R. Sorio, T. Gamucci, I. Wolff, A. Te Velde, J. Lan, J. Verweij

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m². 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.

Original language	English
Pages (from-to)	2019-2022
Number of pages	4
Journal	European Journal of Cancer
Volume	32
Issue number	11
DOIs	https://doi.org/10.1016/0959-8049(96)00226-2
Publication status	Published - Oct 1996

Keywords

Breast cancer
Colorectal cancer
EO9
Gastric cancer
Pancreatic cancer
Phase II study
Proteinuria
Renal toxicity

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/0959-8049(96)00226-2

Fingerprint Dive into the research topics of 'EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group'. Together they form a unique fingerprint.

Cite this

Dirix, L. Y., Tonnesen, F., Cassidy, J., Epelbaum, R., Ten Bokkel Huinink, W. W., Pavlidis, N., Sorio, R., Gamucci, T., Wolff, I., Te Velde, A., Lan, J., & Verweij, J. (1996). EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. European Journal of Cancer, 32(11), 2019-2022. https://doi.org/10.1016/0959-8049(96)00226-2

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. / Dirix, L. Y.; Tonnesen, F.; Cassidy, J.; Epelbaum, R.; Ten Bokkel Huinink, W. W.; Pavlidis, N.; Sorio, R.; Gamucci, T.; Wolff, I.; Te Velde, A.; Lan, J.; Verweij, J.

In: European Journal of Cancer, Vol. 32, No. 11, 10.1996, p. 2019-2022.

Research output: Contribution to journal › Article › peer-review

Dirix, LY, Tonnesen, F, Cassidy, J, Epelbaum, R, Ten Bokkel Huinink, WW, Pavlidis, N, Sorio, R, Gamucci, T, Wolff, I, Te Velde, A, Lan, J & Verweij, J 1996, 'EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group', European Journal of Cancer, vol. 32, no. 11, pp. 2019-2022. https://doi.org/10.1016/0959-8049(96)00226-2

Dirix, L. Y. ; Tonnesen, F. ; Cassidy, J. ; Epelbaum, R. ; Ten Bokkel Huinink, W. W. ; Pavlidis, N. ; Sorio, R. ; Gamucci, T. ; Wolff, I. ; Te Velde, A. ; Lan, J. ; Verweij, J. / EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. In: European Journal of Cancer. 1996 ; Vol. 32, No. 11. pp. 2019-2022.

@article{ad935df1f12b43199a7dba4c0fe206c3,

title = "EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group",

abstract = "In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.",

keywords = "Breast cancer, Colorectal cancer, EO9, Gastric cancer, Pancreatic cancer, Phase II study, Proteinuria, Renal toxicity",

author = "Dirix, {L. Y.} and F. Tonnesen and J. Cassidy and R. Epelbaum and {Ten Bokkel Huinink}, {W. W.} and N. Pavlidis and R. Sorio and T. Gamucci and I. Wolff and {Te Velde}, A. and J. Lan and J. Verweij",

year = "1996",

month = oct,

doi = "10.1016/0959-8049(96)00226-2",

language = "English",

volume = "32",

pages = "2019--2022",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "11",

}

TY - JOUR

T1 - EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group

AU - Dirix, L. Y.

AU - Tonnesen, F.

AU - Cassidy, J.

AU - Epelbaum, R.

AU - Ten Bokkel Huinink, W. W.

AU - Pavlidis, N.

AU - Sorio, R.

AU - Gamucci, T.

AU - Wolff, I.

AU - Te Velde, A.

AU - Lan, J.

AU - Verweij, J.

PY - 1996/10

Y1 - 1996/10

N2 - In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.

AB - In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.

KW - Breast cancer

KW - Colorectal cancer

KW - EO9

KW - Gastric cancer

KW - Pancreatic cancer

KW - Phase II study

KW - Proteinuria

KW - Renal toxicity

UR - http://www.scopus.com/inward/record.url?scp=0030271681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030271681&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(96)00226-2

DO - 10.1016/0959-8049(96)00226-2

M3 - Article

C2 - 8943690

AN - SCOPUS:0030271681

VL - 32

SP - 2019

EP - 2022

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -